BRCA gene mutations in cancer
External reference: https://openalex.org/T10769
-
Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2 Study identifies BRN2-mediated and SHLD2-related resistance to talazoparib in BRCA-mutant breast cancer, proposing combination therapy approaches to improve neoadjuvant treatment outcomes.

